Compare Incyte Corporation (INCY) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Payoneer Global Inc — how do they compare? Incyte Corporation trades at $118.05 (market cap $23.11B), while Payoneer Global Inc trades at $7.11 (market cap $2.41B). The key difference: Incyte Corporation is far larger — about 9.6× Payoneer Global Inc's market cap. Which is the better fit depends on your goals.
| INCY | PAYO | |
|---|---|---|
Market Cap | $23.11B | $2.41B |
Sector | Health | Technology |
52-Week High | $118.52 | $7.42 |
52-Week Low | $67.38 | $4.27 |
Enterprise Value | $19.13B | $2.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Payoneer (PAYO) trades at $7.125, up 0.07% today, with a strong technical outlook as moving averages signal bullish momentum. The company reported revenue of $821.16M in 2025, with a net income margin of 8.57%, though earnings have shown volatility with recent beats and misses. Recent news highlights a pending $2.75 billion acquisition by Nuvei, announced June 15, 2026, which has driven significant investor attention and legal scrutiny over the fairness of the $7.40 per share offer.
The acquisition by Nuvei presents a near-term catalyst, but shareholder lawsuits question the deal price. Analyst consensus is bullish with a $8.20 price target, yet execution risks and integration challenges post-acquisition could impact long-term value. Investors should weigh the premium offered against potential standalone growth prospects in the competitive fintech space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
